Lithium is the most remarkable molecule in psychiatry. It is the only medication proven to prevent suicide, it may protect against Alzheimer's disease, it grows brain gray matter, and its benefits extend far beyond mood stabilization. This is the evidence — all of it — in one place.
This is the most exciting area of lithium research. Over two decades of evidence — from randomized controlled trials to population studies to a landmark 2025 Nature publication — now suggests that lithium deficiency may contribute to Alzheimer's disease, and that even tiny doses of lithium can protect the aging brain.
There is no cure for Alzheimer's. The new monoclonal antibody drugs (lecanemab, donanemab) cost $26,000+/year and carry risks of brain swelling and bleeding. Lithium costs pennies per day, has been used safely for over 70 years, and at low doses produces minimal side effects. If lithium can slow cognitive decline — and the evidence increasingly says it can — this changes everything about how we approach dementia prevention.
Published in Nature — the world's top scientific journal. Lithium was the ONLY metal significantly reduced in brains of people with mild cognitive impairment and Alzheimer's. Lithium gets trapped inside amyloid plaques, draining free lithium from brain tissue. When mice were placed on a lithium-deficient diet, they developed Alzheimer's pathology. Lithium orotate supplementation prevented and reversed it.
This reframes lithium from "psychiatric medication" to "essential brain nutrient."
61 patients with MCI, randomized, double-blind, up to 4 years. Low-dose lithium (blood level 0.25–0.50 mEq/L — well below standard bipolar doses) kept patients cognitively STABLE over 24 months. The placebo group showed progressive decline. Lithium also reduced CSF phosphorylated tau — a key Alzheimer's biomarker. This proved low-dose lithium can halt cognitive decline in the early stages.
Alzheimer's patients received just 300 MICROGRAMS of lithium daily — roughly 1/1000th of a standard bipolar dose — for 15 months. The lithium group maintained stable cognitive scores (MMSE ~20). The placebo group plummeted to 14 — a massive, clinically meaningful decline. Benefits appeared at just 3 months. A microdose so tiny it produces no measurable blood level halted Alzheimer's progression.
University of Pittsburgh, 80 adults age 60+ with MCI, 2-year double-blind trial. The LATTICE trial established feasibility and safety of low-dose lithium in older adults with cognitive impairment. On verbal memory (CVLT-II), the placebo group declined 1.42 points/year while the lithium group declined only 0.73 points/year — a roughly 50% slower decline (p=0.05). No treatment-related serious adverse events. This pilot sets the stage for larger definitive trials.
Entire Danish population registry. Long-term lithium users had significantly lower rates of dementia compared to non-users — even after controlling for psychiatric diagnosis. The protective effect increased with longer duration of use. This was real-world data from an entire country's healthcare system confirming what the clinical trials showed.
Lithium literally grows brain tissue. Multiple MRI studies showed lithium increases gray matter volume by up to 15% in areas critical for attention and emotional regulation. Even HEALTHY volunteers with no psychiatric diagnosis showed increased prefrontal gray matter after just 4 weeks. No other psychiatric medication has ever been shown to grow brain tissue.
Five independent lines of evidence — a Nature study, randomized controlled trials, a microdose study, population registries, and brain imaging — all point in the same direction: lithium protects the brain against cognitive decline. The question is no longer whether lithium is neuroprotective. It is. The question is how to use this knowledge to prevent the coming Alzheimer's epidemic.
Lithium holds a singular distinction in all of psychopharmacology: it is the only medication with replicated, prospective evidence of reducing completed suicide and suicide attempts — independent of its effect on mood episodes. This is not a secondary finding or statistical artifact. It has been reproduced across different study designs, populations, continents, and decades.
Lithium's antisuicidal effect appears to be independent of its mood-stabilizing properties. Patients who don't respond to lithium for mood still show reduced suicidality. The magnitude of suicide reduction is disproportionate to mood stabilization alone, suggesting a separate biological mechanism involving serotonin enhancement and impulse control.
48 RCTs, 6,674 participants. Lithium reduced the risk of suicide by approximately 60% compared to placebo or active comparators. Reduction in completed suicides and deliberate self-harm were both significant. This remains the largest and most cited meta-analysis on any medication and suicide. Nothing else in medicine comes close to this level of evidence for suicide prevention.
Pooled analysis of 34 studies. Suicide and attempts were over 5 times more frequent among patients not on lithium versus those on it. This effect persisted after accounting for diagnosis, concurrent treatment, and illness severity. Discontinuation of lithium was associated with rapid rebound of suicidal risk — especially if stopped abruptly.
All bipolar patients in Sweden, 2005–2013. Lithium reduced suicide-related events by 14% compared to periods without treatment. Critically, valproate — the most commonly prescribed alternative — showed ZERO protective effect against suicide. This real-world data from an entire country proves lithium's anti-suicidal effect is unique, not a class effect of mood stabilizers.
German multicenter registry. Mortality from all causes, including suicide, was 2.7 times lower in patients maintained on lithium versus those who discontinued. Followed patients over a mean of 8+ years. The effect was robust across all affective disorder subtypes.
Bipolar and MDD populations. In patients with depressive episodes and suicidal ideation, lithium augmentation reduced suicidal events by 47% compared to valproate. This study directly compared lithium to the most commonly used alternative, with lithium winning decisively on the primary suicidal outcome.
Swedish national registry, n=11,740. Lithium use was associated with an 82% reduction in violent suicide attempts in a real-world population with bipolar disorder. This confirms that benefits seen in controlled trials translate to real clinical practice and diverse populations.
Abrupt discontinuation of lithium is associated with a sharp rebound in suicidal risk that may exceed baseline rates within weeks. Tondo et al. (2000) showed suicidal acts increased by a factor of 8.85 after lithium was stopped. If lithium must be stopped, taper slowly over at least 2–4 weeks and increase monitoring intensity. Never stop lithium abruptly in a suicidal patient.
One of the most fascinating areas of lithium research: evidence that even naturally occurring TRACE amounts of lithium in drinking water — thousands of times lower than any prescribed dose — have measurable effects on human behavior and health at the population level. Across 7 countries and over 1,286 regions, the pattern is the same.
The definitive meta-analysis: 1,286 regions across Austria, Greece, Italy, Lithuania, UK, Japan, and the USA. Confirmed a statistically significant inverse association: HIGHER lithium in drinking water = LOWER suicide rates. The finding was consistent across multiple countries and cultures. This isn't one study in one place — it's a global pattern.
27 Texas counties, 1978–1987. Counties with higher natural lithium in their water had significantly lower rates of suicide, homicide, rape, robbery, burglary, theft, and arrests for opioid and cocaine possession. Counties with little lithium had higher rates of all of these. The first study to suggest trace lithium affects population behavior.
Independent Japanese studies confirmed the pattern. Ohgami et al. (2009): significant inverse association between lithium in tap water and suicide rates across 18 municipalities. Ishii et al. (2015): higher lithium in water = lower crime rates across Japanese prefectures. The effect held after adjusting for socioeconomic factors.
Texas counties with higher lithium in drinking water had lower Alzheimer's mortality rates. The relationship was dose-dependent — more lithium, less Alzheimer's. Combined with Kessing's Danish data and the Bhatt Nature study, this suggests trace lithium may protect entire populations against dementia without anyone taking a pill.
Before iodine was added to table salt in the 1920s, goiter and thyroid disease were epidemic. Adding trace iodine to salt is now considered one of the greatest public health interventions in history. Multiple researchers have called for investigating whether adding trace lithium to water supplies — similar to fluoride for dental health — could reduce suicide and dementia at the population level. Lithium may be an essential trace element for brain health, just as iodine is essential for thyroid health.
Lithium's remarkable range of benefits stems from a small number of powerful biological mechanisms — each of which has downstream effects across multiple body systems. Understanding these mechanisms explains why lithium protects against suicide, dementia, inflammation, and neurodegeneration simultaneously.
GSK-3 is an enzyme involved in inflammation, cell death, tau phosphorylation (the hallmark of Alzheimer's), and aging. When GSK-3 is overactive, bad things happen. Lithium is one of the most potent natural inhibitors of GSK-3, shutting it down through two independent mechanisms. This single action explains much of lithium's neuroprotective, anti-inflammatory, and anti-aging effects.
Lithium increases Brain-Derived Neurotrophic Factor (BDNF) — essentially fertilizer for neurons. BDNF promotes growth, survival, and repair of brain cells. It is reduced in depression, Alzheimer's, and aging. Lithium's ability to boost BDNF is likely the mechanism behind its unique ability to grow brain gray matter — something no other psychiatric medication can do.
Lithium increases serotonin synthesis and release, and enhances serotonin sensitivity in the prefrontal cortex and limbic system. Low serotonin is the most replicated biological correlate of suicidal behavior across diagnoses. By directly boosting serotonin function, lithium targets the biological substrate of impulsive, violent self-harm.
Elevated neuroinflammation (IL-6, TNF-alpha, CRP) is associated with both suicidal ideation and Alzheimer's disease. Through GSK-3 inhibition, lithium suppresses microglial activation, reduces pro-inflammatory cytokines, and increases anti-inflammatory cytokines (IL-10). This reduces the chronic brain inflammation that drives neurodegeneration.
Lithium promotes autophagy — the cell's process of cleaning up damaged proteins and organelles. This is critical for clearing the toxic protein aggregates (amyloid plaques, tau tangles) that accumulate in Alzheimer's and other neurodegenerative diseases. Lithium does this through a separate pathway (inositol monophosphatase inhibition), giving it two independent mechanisms of neuroprotection.
Many suicides are impulsive acts. Lithium consistently reduces impulsive aggression — a trait that increases vulnerability to acting on suicidal thoughts. This effect is mediated through serotonin and prefrontal cortex stabilization, measurable independently of mood effects. It also explains the drinking water findings: trace lithium may reduce population-level violence and impulsivity.
Many doctors and patients avoid lithium because of its reputation for kidney damage, thyroid problems, and toxicity. That reputation was earned at FULL therapeutic doses (0.6–1.2 mEq/L). But the neuroprotective, anti-suicidal, and anti-dementia benefits described on this page have been demonstrated at doses far below where serious side effects occur. The risk-benefit equation at low doses is completely different.
| Dose Level | Daily Dose | Blood Level | Typical Use | Side Effects |
|---|---|---|---|---|
| Full therapeutic | 900–1800 mg/day | 0.6–1.2 mEq/L | Bipolar mania/maintenance | Tremor, thirst, weight gain, thyroid/renal concerns |
| Low dose | 150–600 mg/day | 0.2–0.5 mEq/L | Augmentation, neuroprotection | Minimal — far fewer side effects |
| Microdose | 300 mcg/day | Not detectable | Cognitive protection | Essentially none |
| Trace (in water) | 70–170 mcg/L | Not measurable | Natural exposure | None — it's in the water |
2-year randomized placebo-controlled trial in elderly patients. Low-dose lithium (target level 0.25–0.50 mEq/L) caused NO impairment of renal function. This directly addresses the #1 concern doctors have about lithium. At low doses, the kidneys are safe.
Thyroid effects are small at low doses. Patients with lithium levels below 0.5 mEq/L had a mean TSH increase of only 0.52 mIU/L — a small, clinically insignificant change. Monitoring is still recommended, but the thyroid risk at low doses is far lower than at full doses. The side effects that make people quit — tremor, urination, cognitive dulling — are MUCH less common at low doses.
80 adults age 60+, 2 years of low-dose lithium. Serious adverse events were 29% in lithium vs. 23% in placebo — and NONE were definitely treatment-related. The most common issues (creatinine changes, diarrhea, tiredness) were similar between groups. The study "established feasibility, confirmed safety and tolerability" for low-dose lithium in older adults.
The safety concerns that rightly apply to full-dose lithium (0.6–1.2 mEq/L) do not apply at the same magnitude to low-dose lithium (0.2–0.5 mEq/L). At low doses, kidney damage has not been demonstrated in controlled trials, thyroid effects are minimal, and the tolerability profile is comparable to many commonly prescribed medications. Standard monitoring (creatinine, TSH, lithium level every 6 months) remains appropriate, but the barrier to prescribing is far lower than many physicians believe.
Beyond protecting the brain, lithium shows evidence of extending lifespan in animals and reducing all-cause mortality in humans. These findings come from multiple species and independent research groups.
Lithium extended lifespan significantly in fruit flies through GSK-3 inhibition and NRF-2 stress response activation. The effect worked even when lithium was first given in mid-to-late life. Even SHORT treatment periods (15 days in early adulthood) prolonged life. In roundworms, lithium at 10 mM increased median lifespan by 46%.
18 Japanese municipalities. Higher lithium levels in drinking water were associated with significantly LOWER all-cause mortality. This wasn't just lower suicide — people in high-lithium areas died less from ALL causes. Combined with the animal data, this suggests lithium may genuinely slow the aging process.
Bipolar patients on long-term lithium had LONGER telomeres than those not on lithium. Telomeres are the protective caps on chromosomes that shorten with age — longer telomeres are associated with slower biological aging. While larger studies have shown mixed results, the convergence of animal lifespan data, population mortality data, and telomere findings paints a compelling picture.
Understanding what makes lithium unique requires seeing what the alternatives DON'T do. No other mood stabilizer, antidepressant, or psychiatric medication can match lithium's range of proven benefits.
| Property | Lithium | Valproate | Lamotrigine | Carbamazepine |
|---|---|---|---|---|
| Prevents suicide | Strong evidence | No | No | No |
| Grows brain gray matter | Yes — up to 15% | No | No | No |
| Reduces dementia risk | Yes — multiple studies | No | No | No |
| Neuroprotective in humans | Robust | Limited | Limited | No |
| Promotes neurogenesis | Yes | Some evidence | No | No |
| Increases BDNF | Yes | Some | Some | No |
| Population-level water benefits | Yes — 7 countries | N/A | N/A | N/A |
| Anti-suicidal independent of mood | Yes | No | No | No |
| Cost per day | ~$0.10 | ~$0.30 | ~$0.50 | ~$0.40 |
The Swedish national population study (Song et al., 2017) directly compared lithium and valproate in all bipolar patients in the country. Lithium reduced suicide-related events by 14%. Valproate showed ZERO protective effect. Clozapine has some anti-suicidal evidence in schizophrenia (~38% reduction), and ketamine shows promise for acute ideation, but neither approaches lithium's breadth and depth of evidence across populations and decades.
| Agent | Antisuicidal Evidence | Quality | Key Limitation |
|---|---|---|---|
| Lithium | Robust, replicated, direct evidence of reducing completed suicides and attempts | Strongest | Requires monitoring; side effects at full doses |
| Clozapine | InterSePT trial showed ~38% reduction in suicidal behavior in schizophrenia | Moderate | Limited to schizophrenia; requires weekly/biweekly blood draws; metabolic effects |
| Ketamine/Esketamine | Rapid reduction in acute suicidal ideation (hours to days) | Emerging | Short-acting; no evidence for sustained suicide reduction; requires in-office administration |
| SSRIs | Treat depression but no direct antisuicidal evidence; FDA black box warning in youth | Weak | May transiently increase suicidal ideation in early treatment |
| Valproate | Swedish population study: ZERO protective effect against suicide | None | No antisuicidal evidence despite widespread use as "mood stabilizer" |
Lithium is not a fringe idea. It is recommended by every major psychiatric guideline, listed on the WHO's Essential Medicines list, and championed by leading researchers worldwide. Yet it remains dramatically underused — largely because no pharmaceutical company profits from promoting a natural element that costs pennies per day.
"Lithium is the most proven, most effective treatment we have in psychiatry. Its underuse is one of the great tragedies of modern medicine."
Lithium is on the WHO Model List of Essential Medicines — recognized as one of the most important medications in all of psychiatry.
Lithium remains a first-line treatment for bipolar disorder and is the only mood stabilizer with recognized anti-suicidal properties in APA guidelines.
Recommends lithium as first-line for bipolar maintenance and acknowledges the anti-suicidal evidence.
Strongly supports lithium as first-line treatment and has published position papers on lithium's neuroprotective properties.
Tufts University. One of the most prominent advocates for lithium's broader use. Has written extensively about the "irrational fear" of lithium among physicians and argues it is dramatically underutilized.
University of Sao Paulo. Pioneer of low-dose lithium for dementia prevention. His 2011 RCT demonstrating cognitive stabilization in MCI was groundbreaking. Continues to advocate for lithium's role in Alzheimer's prevention.
Former head of NIMH Biological Psychiatry. Has emphasized lithium's unique neuroprotective properties and its superiority to anticonvulsant mood stabilizers for long-term brain health.
Psychiatrist and educator whose 2024 publications on low-dose lithium safety ("Lithium: how low can you go?") have been influential in expanding the conversation about lithium beyond traditional use.
Lithium is a naturally occurring element — it cannot be patented, and no pharmaceutical company will ever spend billions marketing it. As a result, it remains underused and underappreciated, while patented medications with far less evidence command the attention of doctors and patients. The newest Alzheimer's drugs cost $26,000+/year with significant side effects. Lithium costs about $0.10/day and has 70+ years of safety data. The evidence on this page exists because researchers believed in the science, not because anyone stood to profit.
This section is designed for family physicians, internists, and psychiatrists who want to consider low-dose lithium for neuroprotection or suicide risk reduction — not just for bipolar mania. The monitoring requirements at low doses are simpler than many physicians realize.
Dehydration (illness, hot weather, exercise) · NSAIDs (ibuprofen, naproxen — increase lithium levels significantly) · ACE inhibitors and ARBs · Thiazide diuretics · Low-sodium diet · New renal impairment · Drug-drug interactions. Patient education about these triggers is as important as the monitoring labs themselves.
If you are not comfortable prescribing lithium yourself, consider referring your patient to a psychiatrist who can initiate and manage lithium while you continue to co-manage the patient's overall care. Many psychiatrists are happy to start lithium and then transfer monitoring back to the primary care physician once stable levels are achieved. The important thing is that the patient gets access to this medication — not who writes the prescription.